Ligand Pharmaceuticals CFO Octavio Espinoza sold 3,057 shares worth $688,000 on March 11, 2026, representing 12.70% of his direct holdings. The sale was executed under a prearranged 10b5-1 plan and appears to be a structured liquidity event rather than a red flag. Despite the insider sale, Ligand's fundamentals remain strong with 2025 revenue reaching $268.1 million (60% increase) and net income of $124.5 million, with management forecasting up to $285 million in revenue for 2026.

Bank of America Securities initiated coverage of Ligand Pharmaceuticals with a Buy rating and $244 price target, highlighting the biopharmaceutical royalty aggregator's differentiated business model, strong management, and attractive growth prospects. The company beat Q4 earnings expectations with $2.02 EPS versus $1.56 consensus and $59.7M in sales versus $55.6M estimate, while maintaining fiscal 2026 guidance of $8.00-$9.00 EPS and $245-$285M in sales.

Ashford Capital Management increased its stake in Vicor by 128,664 shares worth $10.94 million in Q4 2025, bringing its total position to $38.78 million (4.32% of assets). The investment comes as Vicor stock has surged 213% over the past year, driven by strong Q3 results showing 18.5% revenue growth and 57.5% gross margins. The fund's confidence suggests belief in structural demand for Vicor's high-performance power conversion technology in AI and data center infrastructure.

Ashford Capital Management sold 19,607 shares of Cavco Industries (CVCO) worth approximately $11.11 million in Q4 2025, reducing its position from 3.1% to 1.87% of fund assets. The sale appears to be a capital reallocation rather than a loss of conviction, as Cavco's fundamentals remain solid with Q3 revenue up 11.3% year-over-year, though the stock has underperformed the S&P 500 by 1.5 percentage points over the past year.

Ligand Pharmaceuticals announced 2026 full year revenue guidance of $245-$285 million, representing a 15% core revenue growth, with strong expectations for royalty revenue from key pharmaceutical products.

Pelthos Therapeutics signed an agreement with a major Pharmacy Benefit Manager to expand patient access to ZELSUVMI, its FDA-approved topical gel for treating molluscum contagiosum, which affects an estimated 16.7 million people annually.

SQ Innovation received FDA approval for Lasix® ONYU, an at-home subcutaneous treatment for edema in heart failure patients, utilizing Ligand's Captisol technology to create a novel high-concentration furosemide formulation.

Arecor Therapeutics signed a co-development agreement with Sequel Med Tech to combine AT278 insulin with Sequel's automated insulin delivery system, and sold royalty rights to Ligand Pharmaceuticals for up to $11 million, extending their cash runway to 1H 2027.

The global topical drugs Contract Development and Manufacturing Organization (CDMO) market is projected to grow from $46.32 billion in 2024 to $136.71 billion by 2034, with a CAGR of 11.43%. Key growth drivers include increasing demand for non-invasive therapies, advancements in drug delivery technologies, and expanding pharmaceutical outsourcing.

Ligand Pharmaceuticals executives will participate in two upcoming investor conferences: Citi 20th Annual BioPharma Conference in Boston and H.C. Wainwright 27th Annual Global Investment Conference in New York, presenting and hosting investor meetings.

Ligand Pharmaceuticals completed a $460 million convertible senior notes offering due in 2030, using proceeds for general corporate purposes, stock repurchases, and hedge transactions to manage potential stock dilution.

Ligand Pharmaceuticals plans to issue $400 million in convertible senior notes due in 2030, with an option to increase the offering by $60 million. The notes will have a 0.75% interest rate and can be converted into common stock under certain conditions.